Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge
Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge
复制标题
DOI：
10.18383/j.tom.2020.00012
复制
发表时间：
2020-06-01
期刊：
影响因子：
1.9
通讯作者：
Quarles, C. Chad
中科院分区：
文献类型：
--
作者：
Bell, Laura C.;Semmineh, Natenael;Quarles, C. Chad
我们之前已经使用一系列成像协议和软件平台，在12个站点上使用动态磁敏感对比磁共振成像数字参考对象表征了脑肿瘤相对脑血容量（rCBV）的再现性。正如预期的那样，当成像协议和软件一致时，再现性最高，但当它们可变时，再现性降低。本研究的目的是确定rCBV再现性对肿瘤分级和治疗反应分类的影响。我们发现，不同的成像协议和软件平台产生了一系列的肿瘤分级和治疗反应的最佳阈值，但这些阈值的性能是相似的。这些发现进一步强调了跨站点和软件基准测试标准化采集和分析协议的重要性。
We have previously characterized the reproducibility of brain tumor relative cerebral blood volume (rCBV) using a dynamic susceptibility contrast magnetic resonance imaging digital reference object across 12 sites using a range of imaging protocols and software platforms. As expected, reproducibility was highest when imaging protocols and software were consistent, but decreased when they were variable. Our goal in this study was to determine the impact of rCBV reproducibility for tumor grade and treatment response classification. We found that varying imaging protocols and software platforms produced a range of optimal thresholds for both tumor grading and treatment response, but the performance of these thresholds was similar. These findings further underscore the importance of standardizing acquisition and analysis protocols across sites and software benchmarking.